Neuphoria Therapeutics Inc. Common Stock (NEUP) is a publicly traded Healthcare sector company. As of July 2, 2026, NEUP trades at $3.56 with a market cap of $23.62M and a P/E ratio of -17.89. NEUP moved -19.91% today. Year to date, NEUP is -7.07%; over the trailing twelve months it is -49.43%. Its 52-week range spans $2.90 to $21.40. Analyst consensus is neutral with an average price target of $0.00. Rallies surfaces NEUP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Merck Ends Second Alzheimer’s Trial With Neuphoria; Stocks Slide: Merck has terminated a second Alzheimer’s drug trial under its Neuphoria collaboration, stripping the partnership of another key therapeutic candidate and raising questions about its research momentum. Neuphoria’s stock plunged sharply on the news, while Merck shares also declined, reflecting investor concern over future clinical milestones.
| Metric | Value |
|---|---|
| Price | $3.56 |
| Market Cap | $23.62M |
| P/E Ratio | -17.89 |
| EPS | $-0.23 |
| Dividend Yield | 0.00% |
| 52-Week High | $21.40 |
| 52-Week Low | $2.90 |
| Volume | 634.48K |
| Avg Volume | 0 |
| Revenue (TTM) | $15.65M |
| Net Income | $-369.63K |
| Gross Margin | 0.00% |
1 analysts cover NEUP: 0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $0.00.